![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Endocrinol. , 24 May 2024
Sec. Reproduction
Volume 15 - 2024 | https://doi.org/10.3389/fendo.2024.1432697
A correction has been applied to this article in:
Corrigendum: A novel model based on necroptosis to assess progression for polycystic ovary syndrome and identification of potential therapeutic drugs
A Corrigendum on
A novel model based on necroptosis to assess progression for polycystic ovary syndrome and identification of potential therapeutic drugs
By Wang M, An K, Huang J, Mprah R and Ding H (2023). Front. Endocrinol. 14:1193992. doi: 10.3389/fendo.2023.1193992
Incorrect Funding
In the published article, there was a mistake in the Funding statement. The grant number for the Natural Science Foundation of Jiangsu was displayed as BK2021090. The correct grant number is BK20210904.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: polycystic ovary syndrome, diagnostic model, therapeutic drugs, necroptosis, gene signature
Citation: Wang M, An K, Huang J, Mprah R and Ding H (2024) Corrigendum: A novel model based on necroptosis to assess progression for polycystic ovary syndrome and identification of potential therapeutic drugs. Front. Endocrinol. 15:1432697. doi: 10.3389/fendo.2024.1432697
Received: 14 May 2024; Accepted: 15 May 2024;
Published: 24 May 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Wang, An, Huang, Mprah and Ding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Huanhuan Ding, ZGhoQHh6aG11LmVkdS5jbg==
†These authors share first authorship
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.